TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27358262
Drug: Nefopam 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 2.4 mg/ml plus fentanyl 25 µg/ml (NF group)
Study: 27358262
Drug: Fentanyl 25
Normalized name: FENTANYL 25MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 25 µg/ml (SF group)
Study: 23078878
Drug: Reformulated inactivated
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated inactivated chimeric PCV1-2 vaccine (Fostera™ PCV; Pfizer Animal Health), administered as a 2.0 ml dose at 21 days of age.
Study: 18669816
Drug: Subcutaneous etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous etanercept (25 mg) twice weekly
Study: 16433194
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg i.v. once daily for 1-4 days followed by azithromycin 500 mg orally once daily for 3 days
Study: 16433194
Drug: Cefuroxime 1.5
Normalized name: cefuroxime 1.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1.5 g i.v. three times daily for 1-4 days followed by cefuroxime axetil 500 mg orally twice daily for 7 days
Study: 12939210
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (n=151)
Study: 12092741
Drug: Roxifiban (0.75-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxifiban (0.75-1.5 mg; n = 20)
Study: 12092741
Drug: Roxifiban (0.75-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxifiban (0.75-1.0 mg; n = 8)
Study: 12092741
Drug: Roxifiban (0.5-0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxifiban (0.5-0.75 mg; n = 8)
Study: 12092741
Drug: Roxifiban (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxifiban (1.5 or 1.0 mg loading dose with or without 325 mg aspirin; n = 16)
Study: 12092741
Drug: Roxifiban (1.25-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxifiban (1.25-1.5 mg)
Study: 12092741
Drug: Roxifiban (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxifiban (various doses)
Study: 12092741
Drug: Roxifiban with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxifiban with aspirin pretreatment
Study: 10449977
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN; n = 32)
Study: 28759129
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical activity intervention (60 minutes daily for two school years)
Study: 28759129
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (curriculum-defined physical education, 45 minutes twice a week)
Study: 23013506
Drug: 2‐mL glass
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐mL glass tubes
Study: 23013506
Drug: 2‐mL plastic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐mL plastic tubes
Study: 23013506
Drug: 3‐mL plastic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐mL plastic tubes
Study: 23013506
Drug: 4‐mL plastic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐mL plastic tubes
Study: 23013506
Drug: 6‐mL plastic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐mL plastic tubes
Study: 23013506
Drug: 10‐mL glass
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mL glass tubes
Study: 23013506
Drug: 10‐mL plastic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mL plastic tubes
Study: 20519876
Drug: Oral bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral bosentan
Study: 17118684
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 microg plus fluticasone 250 microg twice daily
Study: 15660766
Drug: Zonisamide 100
Normalized name: zonisamide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide 100 mg/day
Study: 11004033
Drug: 300-microg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-microg oral clonidine premedication (n = 18)
Study: 1428380
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g L-Tryptophan (L-TRY) supplementation
Study: 30043572
Drug: Intranasal‐jejunum nutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal‐jejunum nutrient canal placement using clamping pliers under gastroscope guidance
Study: 30043572
Drug: Intranasal‐jejunum nutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal‐jejunum nutrient canal placement using guide wire under gastroscope guidance
Study: 24788875
Drug: Mobic (original
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobic (original product) 4 x 7.5 mg tablets
Study: 24788875
Drug: Melocam (generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melocam (generic product) 4 x 7.5 mg tablets
Study: 23110267
Drug: Capsaicin cream
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin cream (pain group)
Study: 23110267
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (control group)
Study: 18450339
Drug: Participation in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participation in phase II prophylactic HIV vaccine trials
Study: 15657223
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg thrice daily)
Study: 15657223
Drug: Control (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (usual drug treatment)
Study: 12819912
Drug: Epirubicin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 25 mg/m² (Epi25) on a weekly intravenous regimen
Study: 12819912
Drug: Epirubicin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 100 mg/m² (Epi100) on a 4-weekly regimen
Study: 25701454
Drug: Axitinib titration
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib titration (5 mg twice daily during lead-in, followed by stepwise dose increases)
Study: 24140184
Drug: Axitinib titration
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib titration
Study: 18252692
Drug: azithromycin-ER (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: azithromycin-ER (2 g single oral dose)
Study: 18252692
Drug: azithromycin-IR (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: azithromycin-IR (500 mg single oral dose)
Study: 8925582
Drug: Oral L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine hydrochloride (5.6 to 12.6 g/d)
Study: 1507401
Drug: Meropenem (MEPM)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MEPM) at doses of 10, 20, or 40 mg/kg administered by 30-minute drip infusion.
Study: 1507401
Drug: Meropenem (MEPM)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MEPM) at doses of 10 to 20 mg/kg/once, 2 to 3 times a day, maximum dose 173 mg/kg/day q.i.d.
Study: 1507401
Drug: Meropenem (MEPM)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MEPM) treatment.
Study: 1507401
Drug: Meropenem (MEPM)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MEPM) treatment for Staphylococcus aureus.
Study: 1507401
Drug: Meropenem (MEPM)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MEPM) treatment for Streptococcus pneumoniae.
Study: 1507401
Drug: Meropenem (MEPM)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MEPM) treatment for Gram-positive bacteria.
Study: 1507401
Drug: Meropenem (MEPM)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MEPM) treatment for Gram-negative bacteria.
Study: 1507401
Drug: Meropenem (MEPM)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MEPM) treatment for Haemophilus influenzae.
Study: 1507401
Drug: Meropenem (MEPM)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MEPM) treatment for Pseudomonas aeruginosa.
Study: 1507401
Drug: Meropenem (MEPM)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MEPM) treatment for Escherichia coli.
Study: 1507401
Drug: Meropenem (MEPM)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MEPM) treatment for Klebsiella pneumoniae.
Study: 1507401
Drug: Meropenem (MEPM)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MEPM) treatment in cases with previous unsuccessful antibiotic therapies.
Study: 23225026
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human epidermal growth factor (rhEGF) oral spray
Study: 23028263
Drug: Ready-to-use supplementary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ready-to-use supplementary food (RUSF) 46 g daily for 4 months
Study: 17761356
Drug: 5% minoxidil
Normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% minoxidil topical foam (MTF)
Study: 15090413
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost 0.005% once daily for an average duration of 11 months
Study: 11795452
Drug: Microwave treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microwave treatment (maxillary denture microwaved for one minute at 850 Watts, repeated three times)
Study: 11795452
Drug: Control (denture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (denture soak treatment in 0.2% chlorhexidine digluconate solution overnight for 14 days)
Study: 11795452
Drug: Control (denture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (denture soak treatment)
Study: 488520
Drug: Piracetam 2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 2400 mg daily
Study: 21806694
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement (placebo pill)
Study: 19338543
Drug: BoNT‐A injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A injections (200 U or 100 U) followed by hydrodistention (HD)
Study: 16688845
Drug: Early removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early removal of nasogastric tube and early oral feeding (experimental group, n=161)
Study: 11775047
Drug: Extract of
Normalized name: Extract of tomato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extract of Ginkgo biloba (EGb) plus haloperidol (0.25 mg/kg/day)
Study: 11775047
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus haloperidol (0.25 mg/kg/day)
Study: 3878103
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine before propofol injection
Study: 22241354
Drug: Aprepitant (APR)
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant (APR) administered with conventional antiemetic therapy
Study: 22241354
Drug: Conventional antiemetic
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional antiemetic therapy (serotonin receptor antagonist and dexamethasone)
Study: 20424852
Drug: Silicone oil
Normalized name: SILICONE OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone oil suspended with 0.2 mg/ml aspirin (AS SiO)
Study: 18065575
Drug: 2.8 g
Normalized name: glycerin 2.8 GM per 2.7 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.8 g alginate-pectin beverage
Study: 18065575
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g alginate-pectin beverage
Study: 12399698
Drug: Chlorhexidine (CHX)
Normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (CHX) varnish treatment after professional tooth cleaning in mothers with high salivary MS counts
Study: 7594663
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of PRP‐OMP or PRP‐T at 4, 6, and 14 months
Study: 2124027
Drug: T4 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: T4 (0.5 mg daily for 6‐14 days)
Study: 7004624
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CMFT)
Study: 7004624
Drug: Estrogen receptor-positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen receptor-positive tumors (ER+)
Study: 7004624
Drug: Estrogen receptor-negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen receptor-negative tumors (ER-)
Study: 31159856
Drug: Long-term maintenance
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term maintenance antidepressants (citalopram, sertraline, fluoxetine, mirtazapine)
Study: 19106242
Drug: L-alpha-glycerophosphocholine
Normalized name: L-alpha-Glycerophosphocholine
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alpha-glycerophosphocholine
Study: 17302055
Drug: Xiongshao Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiongshao Capsule (XC)
Study: 9756169
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone 2 mg/m2 during radiotherapy
Study: 9756169
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone 4 mg/m2 during radiotherapy
Study: 8161291
Drug: Low-tryptophan diet
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-tryptophan diet (160 mg/d) followed by a drink of 15 amino acids
Study: 26423732
Drug: Garlic-containing meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic-containing meal (100 g white bread, 15 g butter, and 5 g raw, crushed garlic)
Study: 26423732
Drug: Garlic-free control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic-free control meal (100 g white bread and 15 g butter)
Study: 26423732
Drug: Purified garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified garlic extract (0.5 μL/mL) in Mono Mac 6 cells
Study: 12952518
Drug: Soft tissue
Normalized name: INSULIN DETEMIR 14.2 mg in 1 mL SOFT TISSUE IMPLANT [Levemir]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft tissue massage (6 treatments)
Study: 12952518
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, waiting list)
Study: 10663354
Drug: Appropriate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate treatment of endometriosis
Study: 9063757
Drug: Diflunisal (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (500 mg)
Study: 1648849
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite therapy (500 micrograms daily)
Study: 6356320
Drug: sucralfate, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate, 4 g daily
Study: 6356320
Drug: cimetidine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine, 1 g daily
Study: 25567460
Drug: FSP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSP regimen plus a supplement of 'Parma pap' (Group 2)
Study: 21873922
Drug: Home-based computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based computer vergence/accommodative therapy (HBCVAT+)
Study: 21873922
Drug: Home-based pencil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based pencil push-up therapy (HBPP)
Study: 20396714
Drug: artrofoon for
Approvals — FDA: no, EMA: no, PMDA: no
Description: artrofoon for 12 months in addition to basis therapy
Study: 20396714
Drug: basis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: basis therapy
Study: 2927860
Drug: Amnioinfusion with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amnioinfusion with 1000 mL normal saline initially and every 6 hours until delivery
Study: 26364765
Drug: Bepotastine besilate
Normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bepotastine besilate (10 mg orally twice daily for 2 weeks)
Study: 20697755
Drug: Oral home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral home care (Control)
Study: 16494704
Drug: Early discharge
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early discharge at > or = 1650 g
Study: 16494704
Drug: Routine discharge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine discharge at > or = 1800 g
Study: 12970329
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg daily
Study: 9370111
Drug: Etomoxir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomoxir (100 mg/day for 3 days)
Study: 1283591
Drug: Verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 240 mg/day for 14 days
Study: 1283591
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium intake (11 g/day)
Study: 1283591
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium intake (4 g/day)
Study: 4026927
Drug: Sulfadiazine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadiazine (4 mg/kg twice daily, initial dose 8 mg/kg)
Study: 4026927
Drug: Sulfafurazole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfafurazole (50 mg/kg four times a day)
Study: 27909165
Drug: High-dose psilocybin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose psilocybin (22 or 30 mg/70 kg)
Study: 27909165
Drug: Placebo-like dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-like dose (1 or 3 mg/70 kg)
Study: 25141203
Drug: Papacarie™ gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papacarie™ gel for chemo‐mechanical caries removal
Study: 21074011
Drug: Continuous LNG
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous LNG 90 mcg/EE 20 mcg
Study: 19913143
Drug: Cyclic LNG
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic LNG 100 mcg/EE 20 mcg
Study: 17149671
Drug: Provider-delivered, individualized,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider-delivered, individualized, stage-based interventions; details on dosage and duration not available.
Study: 17149671
Drug: Audio-computerized-assisted, self-interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audio-computerized-assisted, self-interviewing systems; details on dosage and duration not available.
Study: 12670085
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + MPTS (scaling and root-planing followed by one dose per pocket of minocycline microspheres, 1 mg)
Study: 8009754
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2.7 g n‐3 fatty acids per day)
Study: 8009754
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (4 1‐g capsules per day)
Study: 2691476
Drug: ticarcillin/clavulanate (3.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticarcillin/clavulanate (3.1 g every 4 h)
Study: 2691476
Drug: gentamicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: gentamicin plus clindamycin (900 mg every 8 h)
Study: 1091001
Drug: Colestipol hydrochloride
Normalized name: Colestipol Hydrochloride
DrugBank: Colestipol (DB00375)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colestipol hydrochloride (5 gm three times daily)
Study: 25504487
Drug: Education and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and daily exercise (4 spinal movements for daily practice)
Study: 22239052
Drug: Eucalyptol-limonene-pinene enteric
Normalized name: pinene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eucalyptol-limonene-pinene enteric soft capsule (C group)
Study: 19845513
Drug: Fixed Atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed Atenolol Amlodipine Combination (FAAC) monotherapy
Study: 19845513
Drug: Fixed Atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed Atenolol Amlodipine Combination (FAAC) in combination therapy
Study: 19845513
Drug: Fixed Atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed Atenolol Amlodipine Combination (FAAC)
Study: 15153724
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of mitoxantrone (6 weekly and 20 fortnightly instillations)
Study: 15153724
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of mitoxantrone (3 fortnightly and 10 monthly instillations)
Study: 15153724
Drug: 100 MU
Normalized name: Tu Mu Xiang
DrugBank: Inula helenium root (DB14350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 MU of IFNalpha‐2b (8 weekly, 8 fortnightly and 6 monthly instillations)
Study: 9652560
Drug: rhIGF‐I 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I 40 microg/kg daily
Study: 9652560
Drug: rhIGF‐I 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I 20 microg/kg daily
Study: 3317057
Drug: 5-ASA at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA at a dosage of 4.8 g per day
Study: 3317057
Drug: 5-ASA at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA at a dosage of 1.6 g per day
Study: 29797519
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg every 12 weeks
Study: 29797519
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg every 8 weeks